TY - JOUR T1 - Rapid detection of SARS CoV-2 N501Y mutation in clinical samples JF - medRxiv DO - 10.1101/2021.04.17.21255656 SP - 2021.04.17.21255656 AU - Sirwan M.A. Al-Jaf AU - Sherko Subhan Niranji Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/20/2021.04.17.21255656.abstract N2 - Severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) variants poses major threats in increasing infectivity, transmission, mortality of Coronavirus Disease 2019 (Covid-19). Additionally, SARS CoV-2 variants resist antibody neutralizations or may abolish vaccine efficacies. Researches to develop economical and fast methods will support the developing or poor countries to challenge the Covid-19 pandemic via tracking common mutations that may help to deploy the vaccination programs and control the virus. Current study has developed a novel low-cost rapid technique, exploiting real time PCR probes and conventional PCR specific primers, to identify N501Y mutation, which was independently emerged in the UK, South African and Brazilian variants. Currently, these variants tend to spread to all over the world and seem to be more infectious, transmissible and fatal. This study helps tracking the N501Y mutation for understanding its clinical and epidemiological characteristics, in those countries where sequencing facilities are lacking or expensive. Further study should focus on other common mutations in the variants of concerns of SARS CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funds were provided for this researchAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Consent forms were filled by the participants and the study was approved by an ethical committee at the Department of Biology, University of Garmian that follow the rules adhered to the Declaration of Helsinki for human and animal research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes). Two mutants and 4 wildtypes PCR products, amplified by conventional PCR amplifying 748 bp in the spike protein at the region of variants of concerns (Figure 3C), were confirmed using Sanger sequencings and the GenBanks (MW897351, MW897352, MW897353, MW897354, MW897355, and MW897356) were released to NCBI data base.https://www.ncbi.nlm.nih.gov/nuccore/MW897351https://www.ncbi.nlm.nih.gov/nuccore/MW897352https://www.ncbi.nlm.nih.gov/nuccore/MW897353https://www.ncbi.nlm.nih.gov/nuccore/MW897354https://www.ncbi.nlm.nih.gov/nuccore/MW897355https://www.ncbi.nlm.nih.gov/nuccore/MW897356 ER -